9 results
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
NPSLE rare, Malar rash ... Evolution: Chronic disease ... Lupusreference #druginduced ... #table #rheumatology ... #diagnosis #management
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... Evolution: Chronic disease ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Cerebrovascular Disease ... autoantibodies that will cause ... CNS #neurology #rheumatology ... cerebritis #diagnosis #management ... #treatment
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome - Treatment ... Ulcers: • Treatment ... #Syndrome #Treatment ... #management #pharmacology ... #rheumatology
Kawasaki Disease (KD) - Diagnosis and Management Summary

Kawasaki Disease (KD) is the most common vasculitis of
Conjunctivitis, Mucositis, Rash ... , Cough • +/-Nausea ... Polymorphous rash ... KD #vasculitis #rheumatology ... #treatment
Hemophilia - Diagnosis and Management
Diagnosis:
 • Consistent bleeding history (unless screening for disease in family members
Diagnosis and Management ... screening for disease ... normal in mild cases ... Avoid meds that ... #treatment #hematology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
• Systemic lupus ... Petechial or purpuric rash ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
NPSLE rare, Malar rash ... Discontinuation of causal ... Lupusreference #DrugInduced ... #Lupus #DIL #rheumatology ... #management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
Muscle atrophy may cause ... had more severe disease ... positive patients Treatment ... Dermatomyositis #diagnosis #management ... #rheumatology #